503B Compounded Drugs Currently in Development at McGuff Outsourcing Solutions (MOS)
We’ve been transitioning our 503A compounding pharmacy to a 503B outsourcing facility and are developing many compounded drugs for when we launch, as well as investigating others to develop in the future.
Our pharmacists are actively testing batches of compounded drugs for the various stages and conducting stability studies.
We're currently actively working on:
- Glutathione
- Methylcobalamin
- Taurine
- Lipoic Acid
- DMPS
- Dexpanthenol
- Procaine
- NAD
We aim to produce Glutathione and Methylcobalamin when the CA BOP first approves our license and we’re officially launched. After that, we plan to produce these other 503B compounded drugs as available:
- Alpha Lipoic Acid (ALA)
- Taurine
- Procaine HCL
Once we’re established in producing these preliminary drugs, we’ll research developing additional drugs such as Methione, Inositol, Choline Chloride (M.I.C.), Calcium EDTA, and more, depending on what is approved for 503Bs and the availability of raw materials.
Stay informed on our latest MOS 503B updates and compounded drug availability at www.mcguff.com/503Bupdate. Contact us with any questions or to be added to our 503B updates mailing list at mos.answers@mcguff.com. Please follow us on social media at @mcguffcompanies.
In the interim, be sure to shop our vast selection of wholesale medical supplies and commercially available pharmaceutical drugs at www.mcguff.com/shop.
